tafolecimab
搜索文档
信达生物_新产品驱动第二季度强劲增长；重申玛仕度肽的有利市场地位-Innovent Biologics (1801.HK)_ Robust 2Q growth driven by new products; reiterate mazdutide's favorable market position
2025-08-08 13:02
8 August 2025 | 12:49AM HKT Innovent Biologics (1801.HK): Robust 2Q growth driven by new products; reiterate mazdutide's favorable market position Solid 2Q sales growth, commercial franchise continues expanding: Innovent reported 2Q25 product revenue to exceed Rmb2.7bn (vs. GSe of Rmb2.68bn, +35% y/y), representing another solid step-up on quarterly sales performance (vs. Rmb2.4bn/Rmb2.0bn in 1Q25/4Q24, +13% q/q). Tyvyt booked US$137mn in 2Q (+19% y/y, or c.Rmb976mn, actual sales recorded by Innovent may di ...